[go: up one dir, main page]

RU2018145512A - Биологические маркеры, которые могут быть использованы в иммунотерапии рака - Google Patents

Биологические маркеры, которые могут быть использованы в иммунотерапии рака Download PDF

Info

Publication number
RU2018145512A
RU2018145512A RU2018145512A RU2018145512A RU2018145512A RU 2018145512 A RU2018145512 A RU 2018145512A RU 2018145512 A RU2018145512 A RU 2018145512A RU 2018145512 A RU2018145512 A RU 2018145512A RU 2018145512 A RU2018145512 A RU 2018145512A
Authority
RU
Russia
Prior art keywords
level
individual
serum
composition
eotaxin
Prior art date
Application number
RU2018145512A
Other languages
English (en)
Other versions
RU2725744C2 (ru
RU2018145512A3 (ru
Inventor
Санг Дзае КИМ
Original Assignee
Джемвакс Энд Каэл Ко., Лтд.
Санг Дзае КИМ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джемвакс Энд Каэл Ко., Лтд., Санг Дзае КИМ filed Critical Джемвакс Энд Каэл Ко., Лтд.
Publication of RU2018145512A publication Critical patent/RU2018145512A/ru
Publication of RU2018145512A3 publication Critical patent/RU2018145512A3/ru
Application granted granted Critical
Publication of RU2725744C2 publication Critical patent/RU2725744C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • G01N33/57585—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/57525—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (23)

1. Способ лечения индивидуума, страдающего от локально-распространенного или метастатического рака поджелудочной железы, включающий:
(a) определение уровня эотаксина (масс./об.) в образце сыворотки индивидуума;
(b) сравнение уровня (a) со средним уровнем эотаксина в сыворотке (масс./об.) в популяции индивидуумов, имеющих локально-распространенный или метастатический рак поджелудочной железы, и если уровень в сыворотке индивидуума по меньшей мере на 10% выше, чем средний уровень в сыворотке,
(c) введение композиции, включающий полипептид, состоящий из SEQ ID NO: 1, индивидууму одновременно с лечением гемцитабином и капецитабином, вследствие чего время выживания увеличивается.
2. Способ по п.1, где капецитабин вводят как 5 фторурацил.
3. Способ по п.1, где композицию вводят в комбинации с гранулоцитарно-макрофагальным колониестимулирующим фактором (GM-CSF).
4. Способ по п.1, где гранулоцитарно-макрофагальный колониестимулирующий фактор (GM-CSF) вводят до введения композиции.
5. Способ по п.1, где композицию вводят парентерально.
6. Способ по п.1, дополнительно включающий измерение уровня CRP (масс./об.) в сыворотке индивидуума после введения, и продолжение введения, если уровень CRP более чем на 10% ниже средней величины в популяции индивидуумов, страдающих от такого же рака.
7. Способ по п.4, где
GM-CSF вводят за 10-15 минут до введения композиции,
GM-CSF и композицию вводят внутрикожно, и
GM-CSF и композицию вводят три раза в течение первой недели лечения, один раз в течение второй, третьей, четвертой, и шестой недель лечения, и один раз каждые четыре недели после этого.
8. Способ лечения индивидуума, страдающего от рака, включающий:
(a) определение уровня эотаксина (масс./об.) в образце сыворотки индивидуума;
(b) сравнение уровня (a) со средним уровнем эотаксина в сыворотке (масс./об.) в популяции индивидуумов, имеющих рак, и если уровень в сыворотке индивидуума по меньшей мере на 10% выше, чем средний уровень в сыворотке,
(c) введение композиции, включающий полипептид, состоящий из SEQ ID NO: 1, индивидууму одновременно с лечением гемцитабином и капецитабином, вследствие чего время выживания повышается.
9. Способ лечения индивидуума, страдающего от локально-распространенного или метастатического рака поджелудочной железы, включающий:
(a) определение уровня эотаксина (масс./об.) в образце сыворотки индивидуума;
(b) определение уровня CRP (масс./об.) в образце сыворотки индивидуума;
(c) сравнение уровня (a) со средним уровнем эотаксина в сыворотке (масс./об.) в популяции индивидуумов, имеющих локально-распространенный или метастатический рак поджелудочной железы;
(d) сравнение уровня (b) со средним уровнем CRP в сыворотке (масс./об.) в популяции индивидуумов, имеющих локально-распространенный или метастатический рак поджелудочной железы; если уровень эотаксина в сыворотке индивидуума по меньшей мере на 10% выше, чем средний уровень сыворотки, и уровень CRP по меньшей мере на 10% ниже чем средний уровень в популяции индивидуумов, страдающих от такого же рака,
(e) введение композиции, включающий полипептид, состоящий из SEQ ID NO: 1, индивидууму одновременно с лечением гемцитабином и капецитабином, вследствие этого время выживания увеличивается.
RU2018145512A 2013-06-07 2014-06-05 Биологические маркеры, которые могут быть использованы в иммунотерапии рака RU2725744C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13171068 2013-06-07
EP13171068.3 2013-06-07
EP14153819 2014-02-04
EP14153819.9 2014-02-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015149010A Division RU2677277C2 (ru) 2013-06-07 2014-06-05 Биологические маркеры, которые могут быть использованы в иммунотерапии рака

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2020121318A Division RU2756548C1 (ru) 2013-06-07 2020-06-26 Биологические маркеры, которые могут быть использованы в иммунотерапии рака

Publications (3)

Publication Number Publication Date
RU2018145512A true RU2018145512A (ru) 2019-01-29
RU2018145512A3 RU2018145512A3 (ru) 2019-07-17
RU2725744C2 RU2725744C2 (ru) 2020-07-03

Family

ID=52008401

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2018145512A RU2725744C2 (ru) 2013-06-07 2014-06-05 Биологические маркеры, которые могут быть использованы в иммунотерапии рака
RU2015149010A RU2677277C2 (ru) 2013-06-07 2014-06-05 Биологические маркеры, которые могут быть использованы в иммунотерапии рака
RU2020121318A RU2756548C1 (ru) 2013-06-07 2020-06-26 Биологические маркеры, которые могут быть использованы в иммунотерапии рака

Family Applications After (2)

Application Number Title Priority Date Filing Date
RU2015149010A RU2677277C2 (ru) 2013-06-07 2014-06-05 Биологические маркеры, которые могут быть использованы в иммунотерапии рака
RU2020121318A RU2756548C1 (ru) 2013-06-07 2020-06-26 Биологические маркеры, которые могут быть использованы в иммунотерапии рака

Country Status (13)

Country Link
US (1) US10383926B2 (ru)
EP (2) EP3004883B1 (ru)
JP (1) JP6059405B2 (ru)
KR (3) KR101552260B1 (ru)
CN (2) CN105535931A (ru)
AU (2) AU2014275610B2 (ru)
BR (1) BR112015030627A2 (ru)
CA (1) CA2912557A1 (ru)
ES (1) ES2927473T3 (ru)
PH (1) PH12015502613B1 (ru)
RU (3) RU2725744C2 (ru)
TW (1) TWI670074B (ru)
WO (1) WO2014196841A1 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2875825B1 (en) 2012-05-11 2017-12-13 KAEL-GemVax Co.,Ltd Composition for preventing or treating rheumatoid arthritis
CN116694597A (zh) 2012-05-11 2023-09-05 珍白斯凯尔有限公司 具有抗炎活性的肽及其在制备抗炎组合物中的应用
JP6272853B2 (ja) 2012-07-11 2018-01-31 ジェムバックス アンド カエル カンパニー，リミティド 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
EP2899201B1 (en) 2012-09-19 2019-09-11 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
EP2899200B1 (en) 2012-09-19 2020-05-06 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
US9907838B2 (en) 2013-04-19 2018-03-06 Gemvax & Kael Co., Ltd. Composition and methods for treating ischemic damage
US10561703B2 (en) 2013-06-21 2020-02-18 Gemvax & Kael Co., Ltd. Method of modulating sex hormone levels using a sex hormone secretion modulator
EP3061459B1 (en) 2013-10-23 2019-12-11 Gemvax & Kael Co., Ltd. Composition for treating and preventing benign prostatic hyperplasia
EP3072519B1 (en) 2013-11-22 2020-08-19 Gemvax & Kael Co., Ltd. Peptide having angiogenesis inhibitory activity and composition containing same
CN105939723B (zh) * 2013-12-17 2020-02-28 珍白斯凯尔有限公司 前列腺癌治疗用组合物
CN106456697B (zh) 2014-04-11 2019-12-17 珍白斯凯尔有限公司 具有纤维化抑制活性的肽和含有其的组合物
US10662223B2 (en) 2014-04-30 2020-05-26 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
KR102413243B1 (ko) * 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3263122B1 (en) 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptide for preventing hearing loss, and composition comprising same
JP7000161B2 (ja) 2015-05-26 2022-01-19 ジェムバックス アンド カエル カンパニー，リミティド 新規ペプチド及びこれを含む組成物
KR102638286B1 (ko) 2015-07-02 2024-02-20 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
CN113476589A (zh) * 2015-11-03 2021-10-08 珍白斯凯尔有限公司 肽在制造用于治疗神经退行性疾病的组合物中的用途
EP4272829A3 (en) 2016-04-07 2024-01-17 Gemvax & Kael Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
GB201803178D0 (en) * 2018-02-27 2018-04-11 Univ Oslo Hf Specific binding molecules for htert
WO2020226498A1 (en) 2019-05-07 2020-11-12 Rijksuniversiteit Groningen Biomarker, kit and method for predicting clinical responsiveness to therapy with an agent that targets alpha4beta7 integrin.
WO2025143530A1 (ko) * 2023-12-28 2025-07-03 주식회사 젬백스앤카엘 Gv1001를 포함하는 우울증의 예방 또는 치료용 약학 조성물

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US425360A (en) * 1890-04-08 Clothes-pounder
HU207799B (en) 1991-07-24 1993-06-28 Beres Export Import Rt Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis
EP0930876B2 (en) 1996-07-22 2010-07-07 Renovo Limited Use of compounds that promote oestrogenic activity for acclerating the healing of skin wounds
US6610839B1 (en) 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US20020165363A1 (en) 1997-05-15 2002-11-07 Koh Sato Cachexia remedy
CA2294782A1 (en) 1997-07-01 1999-01-14 Cambia Biosystems Llc Vertebrate telomerase genes and proteins and uses thereof
US7030211B1 (en) 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
IL132406A0 (en) 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
US6815426B2 (en) 2001-02-16 2004-11-09 E. I. Du Pont De Nemours And Company Angiogenesis-inhibitory tripeptides, compositions and their methods of use
RU2282446C2 (ru) 2001-04-10 2006-08-27 Ниппон Синяку Ко., Лтд. Лекарственное средство для хронического суставного ревматизма
IL158866A0 (en) 2001-05-16 2004-05-12 Yeda Res & Dev Use of il-18 inhibitors for the treatment or prevention of sepsis
WO2003038047A2 (en) 2001-10-29 2003-05-08 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
KR20040107492A (ko) 2002-04-10 2004-12-20 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 섬유증 질병의 치료 및/또는 예방을 위한오스테오프로테게린의 용도
KR20050020987A (ko) 2002-06-12 2005-03-04 바이오겐 아이덱 엠에이 인코포레이티드 아데노신 수용체 길항제를 사용하여 허혈 재관류 손상을치료하는 방법
JP2004137239A (ja) * 2002-10-21 2004-05-13 Bio Oriented Technol Res Advancement Inst 土壌病害防除剤および土壌病害防除方法
WO2005000227A2 (en) 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
WO2004112820A2 (en) 2003-06-25 2004-12-29 Canbas Co., Ltd. Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity
KR20050040517A (ko) 2003-10-29 2005-05-03 주식회사 오리엔트 허혈성 질환에 대한 저항성을 나타내는 형질전환 생쥐
EP1530965B1 (en) 2003-11-11 2006-03-08 Mattern, Udo Controlled release delivery system of sexual hormones for nasal application
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
EP2374458A1 (en) 2005-03-21 2011-10-12 Vicus Therapeutics SPE 1, LLC Combination of an ACE inhibitor and an NSAID for use in ameliorating cachexia/SIRS
KR20080084818A (ko) 2005-11-25 2008-09-19 각고호우징 게이오기주크 전립선암 치료제
JP2009519033A (ja) 2005-12-16 2009-05-14 ディアト 核酸を細胞に送達するための細胞貫通ペプチド結合体
KR100859972B1 (ko) 2006-02-20 2008-09-25 이화여자대학교 산학협력단 막투과 단백질 도메인 펩타이드
JP2009544688A (ja) 2006-07-24 2009-12-17 フォーヒューマンテック カンパニー リミテッド 虚血性疾患の緩和及び治療のための医薬組成物並びにそれを伝達するための方法
CA2676797C (en) 2007-01-29 2014-04-22 Dae Woong Jo Novel macromolecule transduction domains and methods for identification and uses thereof
SG182976A1 (en) * 2007-06-29 2012-08-30 Ahngook Pharmaceutical Co Ltd Predictive markers for ovarian cancer
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
WO2009054996A2 (en) 2007-10-25 2009-04-30 Genelux Corporation Systems and methods for viral therapy
GB2455539B (en) 2007-12-12 2012-01-18 Cambridge Entpr Ltd Anti-inflammatory compositions and combinations
ES2602453T3 (es) 2008-06-16 2017-02-21 Mediolanum Farmaceutici S.P.A. Inmunoterapia antitumoral
KR101043747B1 (ko) 2008-07-16 2011-06-27 주식회사 텔콘 알에프신호의 위상 조정이 가능한 동축케이블 커넥터
ES2334315B1 (es) 2008-07-29 2011-02-28 Universitat Pompeu Fabra Peptidos con capacidad de penetracion celular y sus usos.
JP5337809B2 (ja) 2008-09-22 2013-11-06 日清ファルマ株式会社 抗炎症性ペプチド
JP5826742B2 (ja) 2009-05-07 2015-12-02 ドンコック ファーマシューティカル カンパニー リミテッド 神経損傷及び神経疾患の予防または治療用薬学組成物
EP2251028A1 (en) 2009-05-12 2010-11-17 Biocompatibles Uk Ltd. Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
CA2762551C (en) 2009-05-20 2016-11-22 Toray Industries, Inc. Cell-penetrating peptides
KR20110057049A (ko) 2009-11-23 2011-05-31 박의신 기능성 전립선염 치료제
KR20110062943A (ko) 2009-12-04 2011-06-10 주식회사종근당 퀴나졸린 유도체를 유효성분으로 하는 전립선 비대증 예방 또는 치료제
EP2524039B1 (en) 2010-01-11 2017-11-29 CuRNA, Inc. Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
KR20130024888A (ko) 2010-02-16 2013-03-08 오슬로 유니버시티 하스피탈 에이치에프 폴리펩티드
FR2960542B1 (fr) 2010-05-27 2012-08-17 Esther Suzy Arlette Fellous Peptide en tant que medicament, en particulier pour le traitement du cancer
KR101263212B1 (ko) 2010-05-28 2013-05-10 성신여자대학교 산학협력단 신규한 세포막 투과성 펩타이드 및 그의 용도
WO2011150494A1 (en) 2010-05-30 2011-12-08 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for anticancer compounds
WO2011155803A2 (ko) 2010-06-11 2011-12-15 아주대학교산학협력단 청각보호 작용을 하는 신규 화합물
KR101348284B1 (ko) 2010-09-09 2014-01-03 주식회사 나이벡 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR20120121196A (ko) 2011-04-26 2012-11-05 주식회사 글루칸 관절염 치료제
KR101284772B1 (ko) 2011-05-24 2013-07-17 정종문 항염증, 진통효과를 가지는 기능성 식품 조성물
KR20120133661A (ko) 2011-05-31 2012-12-11 주식회사 바이오포트코리아 아스타잔틴을 포함하는 항염증제
KR101288053B1 (ko) 2011-07-04 2013-07-23 동국대학교 산학협력단 필발 추출물을 유효성분으로 포함하는 내이손상 예방 및 치료용 조성물
KR101361445B1 (ko) 2011-12-26 2014-02-12 성균관대학교산학협력단 펩타이드, 5-플루오로우라실, 및 성숙수지상세포를 포함하는 암 치료용 약학적 조성물
US9303247B2 (en) 2012-02-10 2016-04-05 Hakushinkouseikai Foundation Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine
KR102041381B1 (ko) 2012-03-12 2019-11-27 젬백스 에이에스 능동적인 면역치료법을 이용한 비-소세포성 폐암의 치료
CN116694597A (zh) 2012-05-11 2023-09-05 珍白斯凯尔有限公司 具有抗炎活性的肽及其在制备抗炎组合物中的应用
EP2875825B1 (en) 2012-05-11 2017-12-13 KAEL-GemVax Co.,Ltd Composition for preventing or treating rheumatoid arthritis
JP6272853B2 (ja) 2012-07-11 2018-01-31 ジェムバックス アンド カエル カンパニー，リミティド 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
KR102038487B1 (ko) 2012-09-19 2019-10-30 주식회사 젬백스앤카엘 텔로머라제 펩티드를 포함하는 항균 또는 항진균용 조성물
EP2899199B1 (en) 2012-09-19 2019-07-03 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
EP2899201B1 (en) 2012-09-19 2019-09-11 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
EP2899200B1 (en) 2012-09-19 2020-05-06 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
US9907838B2 (en) 2013-04-19 2018-03-06 Gemvax & Kael Co., Ltd. Composition and methods for treating ischemic damage
US10561703B2 (en) 2013-06-21 2020-02-18 Gemvax & Kael Co., Ltd. Method of modulating sex hormone levels using a sex hormone secretion modulator
EP3061459B1 (en) 2013-10-23 2019-12-11 Gemvax & Kael Co., Ltd. Composition for treating and preventing benign prostatic hyperplasia
EP3072519B1 (en) 2013-11-22 2020-08-19 Gemvax & Kael Co., Ltd. Peptide having angiogenesis inhibitory activity and composition containing same
CN105939723B (zh) 2013-12-17 2020-02-28 珍白斯凯尔有限公司 前列腺癌治疗用组合物
CN106456697B (zh) 2014-04-11 2019-12-17 珍白斯凯尔有限公司 具有纤维化抑制活性的肽和含有其的组合物
US10662223B2 (en) 2014-04-30 2020-05-26 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3263122B1 (en) 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptide for preventing hearing loss, and composition comprising same
CN113476589A (zh) 2015-11-03 2021-10-08 珍白斯凯尔有限公司 肽在制造用于治疗神经退行性疾病的组合物中的用途
KR20170054310A (ko) 2015-11-09 2017-05-17 주식회사 젬백스앤카엘 텔로머라제 유래 펩티드를 포함하는 수지상세포 치료제 및 면역 치료제, 및 이를 사용하는 치료방법

Also Published As

Publication number Publication date
JP6059405B2 (ja) 2017-01-11
EP4063863A1 (en) 2022-09-28
AU2014275610A1 (en) 2015-12-03
RU2725744C2 (ru) 2020-07-03
AU2018229511B2 (en) 2021-07-29
US20160120966A1 (en) 2016-05-05
CN104508485A (zh) 2015-04-08
KR20210005968A (ko) 2021-01-15
CN105535931A (zh) 2016-05-04
KR102201428B1 (ko) 2021-01-12
KR101552260B1 (ko) 2015-09-10
EP3004883B1 (en) 2022-09-14
CN104508485B (zh) 2017-01-18
KR20150004320A (ko) 2015-01-12
KR20150058135A (ko) 2015-05-28
AU2018229511A1 (en) 2018-10-04
RU2756548C1 (ru) 2021-10-01
KR102382190B1 (ko) 2022-04-04
AU2014275610B2 (en) 2018-06-14
BR112015030627A2 (pt) 2017-07-25
RU2015149010A (ru) 2017-07-17
RU2677277C2 (ru) 2019-01-16
CA2912557A1 (en) 2014-12-11
ES2927473T3 (es) 2022-11-07
EP3004883A1 (en) 2016-04-13
US10383926B2 (en) 2019-08-20
TWI670074B (zh) 2019-09-01
EP3004883A4 (en) 2017-06-21
JP2016527197A (ja) 2016-09-08
RU2018145512A3 (ru) 2019-07-17
PH12015502613A1 (en) 2016-02-29
TW201529081A (zh) 2015-08-01
PH12015502613B1 (en) 2016-02-29
WO2014196841A1 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
RU2018145512A (ru) Биологические маркеры, которые могут быть использованы в иммунотерапии рака
EP4219690A3 (en) Methods of cancer treatment using activated t cells
AR094740A1 (es) Antiadhesión de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3
MX2017014381A (es) Metodos terapeuticos y diagnosticos para cancer.
EA201490911A1 (ru) Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина
Pan et al. Pri-miR-34b/c rs4938723 polymorphism is associated with a decreased risk of gastric cancer
Pessina et al. The multidrug-resistance transporter Abcc3 protects NK cells from chemotherapy in a murine model of malignant glioma
EA202191508A1 (ru) Размножение естественных клеток-киллеров и клеток ilc3 с использованием новых ароматических соединений
Singh et al. Idiopathic pulmonary fibrosis: where do we stand and how far to go
BR112018013558A2 (pt) método de tratamento de uma doença hepática em um indivíduo, método de uso de um inibidor de caspase, método para diminuir ou sustentar uma classificação meld ou seus componentes, método para tratar, diminuir ou sustentar uma classificação meld ou seus componentes, método para tratar, diminuir ou sustentar uma classificação de child-pugh ou seus componentes, composição farmacêutica que compreende um inibidor de caspase, kit, método de tratamento, método de tratamento de cirrose hepática e prevenção de uma classificação meld elevada, método de tratamento de cirrose hepática e prevenção de uma classificação de child-pugh elevada
MX2023001622A (es) Celulas dendriticas optimamente activadas que inducen una respuesta inmunologica antitumoral mayor o mejorada.
RU2017101809A (ru) Способы лечения рака и профилактики устойчивости рака к лекарственному средству
AR111380A1 (es) Tratamiento para el asma con anticuerpo anti-tslp
BR112016001775A2 (pt) Composição, métodos de tratamento de um humano que foi diagnosticado com câncer, de prevenção de câncer em um humano com alto risco de ter câncer e de produção de uma composição, de uma população de células nk humanas antitumorais isoladas e de uma população de células dendríticas humanas antitumorais isoladas, células nk e dendríticas humanas isoladas, e, kit
LT2013104A (lt) Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas
De la Rubia et al. Second mobilization and collection of peripheral blood progenitor cells in healthy donors is associated with lower CD34+ cell yields
EA201101663A1 (ru) Ковалентный конъюгат полиэтиленгликоля с гранулоцитарным колониестимулирующим фактором человека
US20210161883A1 (en) Ezh2 inhibitor-induced gene expression
WO2019133358A3 (en) Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
Wahid The role of neuropeptide y in cancer-associated anorexia and its correlation with interleukin-1 beta
Avilés et al. Maintenance Therapy with Interferon-α 2b, Cyclophosphamide, and Prednisone in Aggressive Diffuse Large Cell Lymphoma
Zhou et al. Effects of Passive Immunization against Peptide Tyrosine Tyrosine on the Growth Performance and Endocrine Hormone Levels in Blood Serum of Rats
Lueza et al. Phase III trial of concurrent thoracic radiotherapy with either first-or third-cycle chemotherapy for limited-disease small-cell lung cancer
Roy et al. To determine the feasibility and acceptability of a yoga intervention in cervical carcinoma patients undergoing chemoradiation
Martins et al. Relationships between typically contemporary anomalous experiences, mental disorders and spiritual experiences